viewNemaura Medical Inc

Nemaura Medical appoints Justin Mclarney as chief finance officer

McIarney most recently held the position of senior director, international finance at Lands’ End where he was responsible for all finance teams across the European and Japanese business units 

The UK-based company has developed its continuous glucose monitor sugarBEAT and health subscription service BEATdiabetes

Nemaura Medical Inc (NASDAQ:NMRD), which is developing and commercializing its diabetes diagnostic devices and subscription services, has appointed Justin Mclarney as chief finance officer.

In a statement Friday, CEO Dr Faz Chowdhury called McIarney an “invaluable asset" to the group's leadership team as it continues to grow and execute on its business model.

“His proven track record of driving financial and operational success throughout his career inspires strong confidence as we approach the commercialization phase of our corporate trajectory," Chowdhury said.

READ: Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services

Nemaura said Mclarney brings with him a wealth of experience within international finance, accounting, and process development & control and has been a chartered accountant since 1999. He has a strong track record of driving profitable growth across businesses encompassing ecommerce, retail, logistics, and supply chain operations at an international level. 

McIarney, who started on September 15, has held various senior finance and operational roles, including most recently the position of senior director, international finance at Lands’ End Inc from January 2016 to May 2020 where he was responsible for all finance teams across the European and Japanese business units. 

From February 2007 to September 2015, Mclarney worked for Office Depot in a range of increasingly senior roles culminating in the senior director of finance for the European Contract business. Prior, he spent over 10 years in practice, the final seven years of which was with Ernst & Young LLP.

Mclarney said: “I am very happy to be joining Nemura Medical at such an exciting time. Nemaura has been developing a very exciting platform over a number of years that offers huge potential to directly improve the lives of millions of people both with regard to diabetes as well as other broader and far-reaching health and lifestyle improvements. I look forward to working with Faz and the team as we build and evolve the business to deliver its commercial vision across an International footprint.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Nemaura Medical Inc

Price: 4.12 USD

Market: NASDAQ
Market Cap: $94.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read